Misty Wayman
Obstetrics & Gynecology · Oklahoma City, OKNPI 1285693408
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,634 of the $13,174 with a category attached, or 65.5%. 48 manufacturers reported payments, led by Intuitive Surgical at 35.4% of the total. 2025 is the largest year on record at $5,508, 6.6 times the $838 reported in 2019. Among obstetrics & gynecology clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 452 payments — averaging $29.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- AbbVie$2K
- Mayne Pharma Commercial LLC$719
- Gynesonics, Inc.$653
- Organon$644
- Bayer$497
- plus $4K from 42 others
What the payments were for
- Speaking & faculty fees$5004%
- Food & beverage$8,63466%
- Education$4,04031%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,174 in reported general payments places this provider in the 95th percentile of 396 obstetrics & gynecology providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VeozahFezolinetant | 11 | $5,883 |
| ProgesteroneProgesterone, Micronized | 38 | $1,975 |
| Estradiol | 33 | $1,047 |
| Liothyronine Sodium | 14 | $917 |
| Levothyroxine Sodium | 33 | $516 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncVeozah | $381 | $5,88311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 396 obstetrics & gynecology providers in Oklahoma.
Other obstetrics & gynecology in Oklahoma City
- Tori OdanielOklahoma City$917K
- Kathleen MooreOklahoma City$795K
- Beverly VavrickaOklahoma City$22K
- Monica ReidOklahoma City$20K
- Hoda MaaroufOklahoma City$15K
- Catherine HildebrandOklahoma City$12K
- Catherine GardnerOklahoma City$12K
- Kamal ShanbourOklahoma City$10K
- Darren GoffOklahoma City$10K
- Lisa CheekOklahoma City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.